Astrazeneca Pharma India Limited (ASTRAZEN)

Loading page…

Astrazeneca Pharma India Limited (ASTRAZEN) · mywealthgrid

About

AstraZeneca Pharma India Limited operates in pharmaceuticals within India's healthcare sector, generating quarterly revenues of ₹526–683 Cr. With a market capitalization of ₹19,382.5 Cr, it represents a significant player in the Indian pharmaceutical market. The company has shown revenue growth momentum, with recent quarters reflecting increases from the prior-year period.

Face value: ₹2

Market cap

₹15,078 Cr

P/E

88.9×

P/B

17.3×

Dividend yield

0.6%

ROE

22.8%

ROCE

28.7%

Debt / equity

OPM

11.5%

EPS (TTM)

₹67.8

Book value

₹349.1

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Margin compression: operating profit margin declined from 17.98% (Mar 2025) to 7.17% (Jun 2026), creating earnings volatility despite revenue growth

Earnings unpredictability: net profit and EPS swing significantly quarter-to-quarter (net profit ranged ₹30.85–₹58.25 Cr over 8 quarters) with no clear correlation to revenue — verify drivers of cost volatility and product-mix changes

Valuation concern: PE of 114.27 is elevated while the stock has declined 11.13% over 1 year and trades near its 52-week low (₹7,753 vs ₹9,827.5 range) — verify if earnings recovery is expected

Regulatory and pricing pressure typical to Indian pharma — verify ongoing price controls, compliance costs, and generic competition exposure

Generated analysis · source review pending

Growth drivers

Revenue momentum: growth from ₹526.31 Cr (Jun 2025) to ₹682.79 Cr (Jun 2026) (+29.8% YoY) and consistent quarter-over-quarter expansion; verify if driven by volume, new products, or pricing

Strong capital efficiency at ROE of 22.82% provides scope for reinvestment or shareholder returns; verify if this efficiency can extend to margin expansion given recent OPM decline

Zero debt position (D/E 0) enables financial flexibility for growth initiatives; verify capex and R&D spending plans or potential acquisitions

Consistent dividend history (paid annually for past 4+ years) shows stable cash generation; verify if dividend growth is planned alongside revenue expansion

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹6,031.0-3.6%1Y

Quick read

rule-based

Pros

+Strong return on equity of 21.1% (3-yr avg)
+High return on capital employed of 30.9%
+Revenue CAGR of 22.8% over the last 5 years
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 58.3×
+Dividend payout of 53.1% of profit
+High promoter holding of 75% with no pledge

Cons

−Expensive at 88.9× trailing earnings
−Trading at 17.3× book value

Research score

Structured signal from quality, growth, valuation and momentum.

48/100

Business quality: 74
Growth

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	564	117	117	728	832	814	806	1,003	1,296	1,716	2,276
COGS	-199	38	38	231	305	295	312	360	595	963	1,381
Gross profit	—	79	79	497	527	519	494	643	701	753	895
	746	78	78	426	406	383	407	478	517	499	633
	16	1	1	71	121	135	86	165	184	254	262
OPM %	2.9%	0.6%	0.6%	9.8%	14.5%	16.7%	10.7%	16.5%	14.2%	14.8%	11.5%
Depreciation	17	4	4	15	19	20	17	16	15	40	29
Interest	—	0	0	0	1	1	1	1	1	1	4
	7	1	1	16	13	13	15	-14	51	-56	23
Profit before tax	6	-2	-2	73	114	127	83	134	220	156	252
Tax	—	8	8	18	42	34	21	35	58	41	65
Tax %	—	380.4%	380.4%	25.1%	36.6%	26.6%	25.8%	26%	26.4%	26%	25.7%
	5	-10	-10	54	72	93	62	99	162	116	188
PAT margin %	0.9%	-8.2%	-8.2%	7.5%	8.7%	11.5%	7.7%	9.9%	12.5%	6.7%	8.2%
EPS (₹)	2.1	-3.8	-3.8	21.8	28.9	37.3	24.6	39.7	64.6	46.3	75
EPS adjusted (₹)	—	-3.8	-3.8	21.8	28.9	37.3	24.6	39.7	64.6	46.3	75
	0%	—	—	0%	3.5%	5.4%	40.6%	40.3%	37.2%	69.1%	48%
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	5	5	5	5	5	5	5	5	5	5
Reserves	198	242	296	359	451	506	584	707	765	868
	—	—	—	—	—	0	0	0	0	0
	245	214	261	342	319	345	396	366	748	1,116
Total equity & liabilities	449	461	562	706	775	857	985	1,078	1,518	1,989
	97	75	75	60	70	74	69	62	64	117
CWIP	6	4	7	24	4	2	1	0	0	0
Investments	0	—	—	—	—	0	0	57	0	0
	345	382	480	622	701	780	915	958	1,454	1,872
Total assets	449	461	562	706	775	857	985	1,078	1,518	1,989

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	68.3%	63.3%	63.7%	61.3%	64.1%	54.1%	43.9%	39.3%
EBITDA margin %	9.8%	14.5%	16.7%	10.7%	16.5%	14.2%	14.8%	11.5%
EBIT margin %	7.7%	12.3%	14.2%	8.6%	14.8%	13.1%	12.5%	10.3%
PAT margin %	7.5%	8.7%	11.5%	7.7%	9.9%	12.5%	6.7%	8.2%
Working capital
Receivable days	40	37	38	39	39	43	39	34
Inventory days	187	197	198	164	193	140	208	272
Payable days	266	251	221	223	231	122	173	207
NWC days	-39	-17	15	-20	1	61	74	99
Leverage
Current ratio	1.56	1.66	2.04	2.12	2.31	2.61	1.91	1.76
Debt to EBITDA	—	—	—	0	0	0	0	0
Debt to equity	—	—	—	0	0	0	0	0
Interest coverage	—	101	117.6	88.4	277.7	170.3	174.4	58.3
Asset turnover	1.3	1.18	1.05	0.94	1.02	1.2	1.13	1.14
Return ratios
Return on assets %	9.7%	10.2%	12%	7.2%	10.1%	15%	7.6%	9.4%
Return on capital employed %	26.1%	33.8%	30.1%	16.9%	31.1%	30.9%	33.2%	28.7%
Return on equity %	18.1%	19.8%	20.5%	12%	16.9%	22.7%	15%	21.5%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	75%	75%	75%	75%	75%	75%	75%	75%	75%	75%	75%	75%
	2.69%	2.65%	2.74%	2.79%	2.9%	2.93%	2.89%	3.03%	2.74%	2.71%	2.78%	2.68%
	2.43%	2.78%	3.78%	5.01%	5.1%	5.22%	4.65%	4.56%	5.26%	5.56%	5.8%	6.08%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	19.88%	19.57%	18.48%	17.2%	17%	16.85%	17.46%	17.41%	17%	16.73%	16.42%	16.24%
No. of shareholders	—	—	—	—	—	—	—	—	32,914	31,551	29,007	29,338

Promoter holding up 0 percentage points since Sep 2023.

10 deals · 19 Sept 2022 – 7 Oct 2024

Date	Client	Type	Venue	Side	Quantity	Price	Value
7 Oct 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	1,25,166	₹7,884.41	₹98.69 Cr
7 Oct 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	1,25,166	₹7,887.16	₹98.72 Cr
30 Sept 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	1,27,119	₹7,804.96	₹99.22 Cr
30 Sept 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	1,27,119	₹7,802.00	₹99.18 Cr
24 Sept 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	1,31,308	₹7,499.17	₹98.47 Cr
24 Sept 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	1,31,308	₹7,506.36	₹98.56 Cr
19 Sept 2022	ISHARES CORE MSCI EMERGING MARKETS ETF	Block	BSE	Buy	74,097	₹3,152.55	₹23.36 Cr
19 Sept 2022	ISHARES CORE EMERGING MARKETS MAURITIUS CO	Block	BSE	Sell	74,097	₹3,152.55	₹23.36 Cr
19 Sept 2022	ISHARES MSCI INDIA SMALL-CAP ETF	Block	BSE	Buy	6,542	₹3,152.55	₹2.06 Cr
19 Sept 2022	ISHARES INDIA SC MAURITIUS COMPANY	Block	BSE	Sell	6,542	₹3,152.55	₹2.06 Cr

1–10 of 10

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Ms. SHILPA DIVEKAR NIRULANon-Executive - Independent Director-Chairperson
Ms. REVATHY ASHOKNon-Executive - Independent Director
Ms. MONICA WIDHANINon-Executive - Independent Director
Mr. PRAVEEN RAO AKKINEPALLYExecutive Director
Ms. HOOI BIEN CHUAHNon-Executive - Non Independent Director
Ms. BHAVANA AGRAWALExecutive Director
Ms. Tanya SanishCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 4 fund houses

Held by these funds

5.33%

of the company's equity

All mutual funds

6.01%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

18 schemes · 4 fund houses

		Shares
SMALL CAP FUND	Nippon India Mutual Fund	6.62 L	460.1	0.56%	2.648%	-0
Healthcare FundNEW	ICICI Prudential Mutual Fund	2 L	138.86	1.99%	0.799%	—
Quality Fund	ICICI Prudential Mutual Fund	81,005	56.31	2.63%	0.324%	-0
Multi Cap FundNEW	ICICI Prudential Mutual Fund	78,271	54.41	0.28%	0.313%	—
Innovation Fund	ICICI Prudential Mutual Fund	76,227	52.99	0.66%	0.305%	+29,472
PHARMA FUND	Nippon India Mutual Fund	62,568	43.49	0.46%	0.25%	-0
Small Cap FundNEW	ICICI Prudential Mutual Fund	33,970	23.61	0.24%	0.136%	—
Small Cap Fund	Baroda BNP Paribas Mutual Fund	32,200	22.38	1.71%	0.129%	-0

1–8 of 18

1 / 3

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

26 announcementsExport CSV

18 Sept 2026, 4:56 pmCompany Update

Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order

Award of Order / Receipt of Order PDF

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	68.3%	63.3%	63.7%	61.3%	64.1%	54.1%	43.9%	39.3%
EBITDA margin %	9.8%	14.5%	16.7%	10.7%	16.5%	14.2%	14.8%	11.5%
EBIT margin %	7.7%	12.3%	14.2%	8.6%	14.8%	13.1%	12.5%	10.3%
PAT margin %	7.5%	8.7%	11.5%	7.7%	9.9%	12.5%	6.7%	8.2%
Working capital
Receivable days	40	37	38	39	39	43	39	34
Inventory days	187	197	198	164	193	140	208	272
Payable days	266	251	221	223	231	122	173	207
NWC days	-39	-17	15	-20	1	61	74	99
Leverage
Current ratio	1.56	1.66	2.04	2.12	2.31	2.61	1.91	1.76
Debt to EBITDA	—	—	—	0	0	0	0	0
Debt to equity	—	—	—	0	0	0	0	0
Interest coverage	—	101	117.6	88.4	277.7	170.3	174.4	58.3
Asset turnover	1.3	1.18	1.05	0.94	1.02	1.2	1.13	1.14
Return ratios
Return on assets %	9.7%	10.2%	12%	7.2%	10.1%	15%	7.6%	9.4%
Return on capital employed %	26.1%	33.8%	30.1%	16.9%	31.1%	30.9%	33.2%	28.7%
Return on equity %	18.1%	19.8%	20.5%	12%	16.9%	22.7%	15%	21.5%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Date	Category	Subject	Filing
18 Sept 2026, 4:56 pm	Company Update Award of Order / Receipt of Order	Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order	PDF
15 Sept 2026, 4:45 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
15 Sept 2026, 12:00 pm	Company Update General	Information Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Resignation Of Senior Management Personnel	PDF
2 Sept 2026, 6:15 pm	Company Update General	Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Disclosure Of ESG Rating	PDF
25 Aug 2026, 9:16 pm	Company Update Award of Order / Receipt of Order	Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order	PDF
24 Aug 2026, 8:52 pm	Company Update General	Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Disclosure Of ESG Rating	PDF
21 Aug 2026, 10:24 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	PDF
15 Aug 2026, 3:41 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	PDF

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	38	9	55	87	105	101	58	93	65	-15
	0	-9	-2	202	173	5	18	22	31	19
	0	0	6	-379	-9	-9	-24	-44	-66	-92
Net cash flow	38	-1	59	-90	269	96	52	70	31	-88
Free cash flow	32	3	36	73	97	91	50	82	64	-19
CFO / Operating profit %	—	—	77.1%	72.4%	77.4%	117%	35.3%	50.2%	25.7%	-5.8%

Astrazeneca Pharma India Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Events

Announcements

Not in the F&O segment

Announcements

Annual reports

13

1

Compounded sales growth

Compounded profit growth

Return on equity

Astrazeneca Pharma India Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Events

Announcements

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Not in the F&O segment

Announcements

Annual reports

Dividends13

Board meetings1

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

13

1